UiPath, which develops AI-based bots that automate mundane enterprise tasks, says its total Series C was $265M, up from $225M in September
UiPath, a startup that works in the growing area of RPA, or robotic process automation — where AI-based software is used to help businesses run repetitive …
Context & Ripple Effects
UiPath's funding cadence has been compressing all year: a ~$120M Series B at a $1B+ valuation in March, then a $225M Series C at $3B from CapitalG, Sequoia, and Accel in September. Today's disclosure that the same round closed at $265M means existing investors topped up within weeks — a signal that demand for RPA exposure outran even the September allocation.
The round sits mid-way through an extraordinary ladder: from a $30M Series A in 2017 to a $568M Series D at $7B in April 2019 and a $225M Series E at $10.2B by mid-2020. This upsizing is the moment the private-market appetite for enterprise automation became self-reinforcing.
First-order effects
- UiPath banks an extra $40M of Series C capital without a new round's dilution or process cost, extending runway for enterprise sales and product expansion while CapitalG, Sequoia, and Accel deepen their positions at the same $3B terms.
Second-order effects
- A $265M war chest at a $3B valuation raises the fundraising bar for rival RPA vendors, forcing competitors to either raise comparable rounds or cede the enterprise back-office segment to UiPath's sales capacity.
Third-order effects
- The pattern — successive mega-rounds at rapidly compounding valuations — concentrates RPA around one capital-rich leader, but the corpus's later arc shows the reckoning: a FY2026 guidance miss that sent PATH down over 15%, a CEO handback to co-founder Daniel Dines, and a 30%+ stock drop, as private-market growth math met public-market scrutiny.
The trend: Enterprise RPA is consolidating into a venture-capital-fueled leader whose private hyper-growth must eventually answer to public-market discipline on growth and guidance.